GlassScriptPhysician profile
Joseph Brierre
NPI 1316918394
$4,885.77
in general payments reported to CMS, 2019-2025
50 companies · $854 in 2025
The $854 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $366 · 2021: $364 · 2022: $584 · 2023: $545 · 2024: $729 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,128.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $492.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $448.92 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $366.57 | 2019-2025 | Krazati, Opdivo |
| Novartis Pharmaceuticals Corporation | $335.29 | 2021-2025 | |
| Amgen INC. | $290.88 | 2019-2022 | |
| Celgene Corporation | $282.04 | 2019-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $244.51 | 2019-2025 | Lynparza, Calquence |
| Janssen Biotech, INC. | $234.17 | 2019-2025 | Darzalex, Carvykti, Imbruvica |
| Gilead Sciences, INC. | $181.73 | 2019-2025 | Trodelvy |
| Daiichi Sankyo INC. | $136.97 | 2024-2025 | Enhertu, Datroway |
| Exelixis INC. | $128.02 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $120.46 | 2020-2024 | Brukinsa |
| Eisai INC. | $118.28 | 2019-2025 | |
| Genzyme Corporation | $117.82 | 2019-2025 | |
| Lilly USA, LLC | $111.75 | 2019-2023 | Verzenio, Jaypirca |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Brierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.